{"id":"aceclidine-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular discomfort or irritation"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Brow ache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aceclidine works by activating muscarinic acetylcholine receptors on the ciliary muscle and iris sphincter in the eye. This parasympathomimetic action causes contraction of the ciliary muscle (accommodation) and pupil constriction, which can improve near vision and potentially reduce intraocular pressure. The ophthalmic solution formulation allows direct local delivery to ocular tissues.","oneSentence":"Aceclidine is a cholinergic agonist that stimulates muscarinic receptors in the eye to increase accommodation and improve near vision.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:05.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Presbyopia (age-related loss of accommodation)"},{"name":"Potentially glaucoma or ocular hypertension"}]},"trialDetails":[{"nctId":"NCT05728944","phase":"PHASE3","title":"Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2023-03-06","conditions":"Presbyopia, Near Vision, Refractive Error","enrollment":229},{"nctId":"NCT05656027","phase":"PHASE3","title":"Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2022-12-19","conditions":"Presbyopia, Refractive Error, Eye Diseases","enrollment":469},{"nctId":"NCT06045299","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia","status":"COMPLETED","sponsor":"Corxel Pharmaceuticals","startDate":"2023-09-27","conditions":"Presbyopia, Near Vision, Miosis","enrollment":300},{"nctId":"NCT05753189","phase":"PHASE3","title":"Phase 3 Safety Study for the Treatment of Presbyopia Subjects","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2023-02-21","conditions":"Presbyopia, Near Vision, Miosis","enrollment":362},{"nctId":"NCT05431543","phase":"PHASE2","title":"Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2022-08-06","conditions":"Presbyopia, Refractive Errors, Eye Diseases","enrollment":59},{"nctId":"NCT05294328","phase":"PHASE2","title":"Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2022-05-05","conditions":"Presbyopia, Refractive Errors, Eye Diseases","enrollment":68},{"nctId":"NCT06270030","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia","status":"COMPLETED","sponsor":"Corxel Pharmaceuticals","startDate":"2024-03-04","conditions":"Presbyopia","enrollment":21},{"nctId":"NCT05936489","phase":"PHASE1","title":"Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2023-07-06","conditions":"Eye Diseases, Presbyopia, Refractive Errors","enrollment":30},{"nctId":"NCT03201562","phase":"PHASE2","title":"A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2017-04-30","conditions":"Presbyopia","enrollment":58},{"nctId":"NCT02554396","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2015-09","conditions":"Presbyopia","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LNZ100","Aceclidine"],"phase":"phase_3","status":"active","brandName":"Aceclidine ophthalmic solution","genericName":"Aceclidine ophthalmic solution","companyName":"LENZ Therapeutics, Inc","companyId":"lenz-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aceclidine is a cholinergic agonist that stimulates muscarinic receptors in the eye to increase accommodation and improve near vision. Used for Presbyopia (age-related loss of accommodation), Potentially glaucoma or ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}